First RCT provides reassurance about the use of antiplatelet therapy after ICH

Uncertainty about when – or if – to restart antithrombotic therapy in patients who have survived intracerebral haemorrhage (ICH) may be clearer after extended follow up data from the first RCT to investigate the dilemma, suggests its reintroduction is safe and has no statically significant effect on risk of recurrent ICH. The UK trial of ...

Already a member?

Login to keep reading.

© 2021 the limbic